Literature DB >> 23619327

Therapeutic plasma exchange in patients with neurological diseases: multicenter retrospective analysis.

Emin Kaya1, Muzaffer Keklik, Mehmet Sencan, Mehmet Yilmaz, Ali Keskin, Ilhami Kiki, Mehmet Ali Erkurt, Serdar Sivgin, Serdal Korkmaz, Vahap Okan, Mehmet Hilmi Doğu, Ali Unal, Mustafa Cetin, Fevzi Altuntaş, Osman Ilhan.   

Abstract

Therapeutic plasma exchange (TPE), is a procedure, changing pathologic substances in the plasma of patients with replacement fluid. TPE has an increasing list of indications in recent years such as neurological, connective tissue, hematological, nephrological, endocrinological and metabolic disorders. We report our multicenter data about therapeutic plasma exchange in patients with neurological diseases. Six University Hospitals' aphaeresis units medical records about neurologic diseases were reviewed retrospectively. Hundred and fifteen patients and 771 TPE sessions from six aphaeresis units' were included to this study. Of the 115 patients, 53 (46%) were men and 62 (54%) were women. The median age was 50 (range: 5-85) years. Of these patients 58.3% were Guillain-Barre syndrome (GBS), 17.4% were acute disseminated encephalomyelitis (ADEM), 10.4% were chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 7% were multiple sclerosis, 6.1% were myasthenia gravis (MG) and 0.9% were Wilson disease (WD). The median number of TPE sessions per patient was 5 (range 1-72). Human albumin was used as a replacement fluid in 66% and fresh frozen plasma was used in 34% of cases. TPE was done through central venous catheters in 66%, and peripheral venous access in 34% of patients. Some complications were seen in patients (18.3%) during TPE sessions. These complications were, complications related to catheter placement procedure (8.7%), hypotension (3.5%), hypocalcaemia (3.5%) and allergic reactions (1.7%). The complication ratios were 2.7% in total 771 TPE procedures. TPE procedure was terminated in 6% of sessions depending on these complications. Overall responses to TPE were noted in 89.5% of patients. In conclusion; Therapeutic plasma exchange is an effective treatment option in several neurologic diseases.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23619327     DOI: 10.1016/j.transci.2013.04.015

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  7 in total

1.  Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Review of 63 Cases.

Authors:  Anil Tombak; Mehmet Ali Uçar; Aydan Akdeniz; Arda Yilmaz; Hakan Kaleagası; Mehmet Ali Sungur; Eyup Naci Tiftik
Journal:  Indian J Hematol Blood Transfus       Date:  2016-02-22       Impact factor: 0.900

2.  Therapeutic Plasma Exchange as a Treatment for Autoimmune Neurological Disease.

Authors:  Ivana Nieto-Aristizábal; Álvaro J Vivas; Pablo Ruiz-Montaño; Cristian C Aragón; Iván Posso-Osorio; Jairo Quiñones; Julián Alejandro Rivillas; Gabriel J Tobón
Journal:  Autoimmune Dis       Date:  2020-07-31

3.  Therapeutic plasma exchange for refractory SLE: A comparison of outcomes between different sub-phenotypes.

Authors:  Aynur Soyuöz; Ömer Karadağ; Tülay Karaağaç; Levent Kılıç; Şule Apraş Bilgen; Osman İlhami Özcebe
Journal:  Eur J Rheumatol       Date:  2017-12-07

4.  Assessment of Hemostasis after Plasma Exchange Using Rotational Thrombelastometry (ROTEM).

Authors:  Gerold Thölking; Rolf Mesters; Ralf Dittrich; Hermann Pavenstädt; Philipp Kümpers; Stefan Reuter
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

5.  Guillain-Barre syndrome: Demographics, clinical profile & seasonal variation in a tertiary care centre of central India.

Authors:  Manisha Shrivastava; Shah Nehal; Navaid Seema
Journal:  Indian J Med Res       Date:  2017-02       Impact factor: 2.375

6.  Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients.

Authors:  Johannes Ehler; Sebastian Koball; Martin Sauer; Steffen Mitzner; Heiko Hickstein; Reiner Benecke; Uwe K Zettl
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

Review 7.  Biological Drugs in Guillain-Barré Syndrome: An Update.

Authors:  Nazgol Motamed-Gorji; Nassim Matin; Omidreza Tabatabaie; Piero Pavone; Catia Romano; Raffaele Falsaperla; Giovanna Vitaliti
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.